Drug Approval | October 31, 2022
USFDA issues Form-483 for Lupin's Nagpur Unit-2
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
India will become a digital health leader, as we have the world’s best technical manpower required and our data is the cheapest in the world, approaching 100 percent coverage
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
The newest facility has all the core specialties like Obstetrics and Gynaecology, Orthopaedics, Neurology, Cardiology, Paediatrics, General Surgery, and Urology
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
CGHS would give robust coverage to pensioners and with new innovations and practices
He also highlighted the need for community awareness for continued implementation of the Covid Appropriate Behaviour (CAB) especially in view of the upcoming festival season
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
Subscribe To Our Newsletter & Stay Updated
